AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, today announces that preclinical data on its drug candidate recAP, to treat the ultra rare disease Hypophosphatasia, have been published in the journal Bone. The senior investigator of the study is Dr. José Luis Millán, of Sandford-Burnham Medical Research Institute, La Jolla, CA, USA, and world-leading researcher in Hypophosphatasia.